GSTM1 and varicose disease: After adjusting for variables including painless endoscopic therapy, endoscopic therapy frequency, lymphocyte, Hb, AST, varices status, spleen thickness, ascites grade and shock, the risk of rebleeding after endoscopic therapy in patients with endoscopic primary prophylaxis decreased by 0.858 times in comparison with those without endoscopic primary prophylaxis (OR = 0.142, 95%CI: 0.066–0.304, P < 0.001).